The Safety and Feasibility of Laparoscopic Gastrectomy after Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
Table 1
Baseline, demographics, and clinical features of cases in this study.
Demographics and clinical features
LAG
OG
value
N = 77 (%)
N = 76 (%)
Age (years)
60.4 ± 9.4
59.3 ± 10.6
0.675
Gender
0.295
Male
53 (66.8)
59 (77.6)
Female
24 (31.2)
17 (22.4)
BMI (kg/m2)
23.0 ± 3.2
23.7 ± 2.9
0.188
Hemoglobin (g/L)
123.9 ± 17.3
120.9 ± 21.4
0.487
Albumin (g/L)
42.3 ± 2.9
42.0 ± 3.2
0.434
Tumor size
3.6 ± 1.7
4.5 ± 2.6
0.038
Longitudinal location
0.329
Esophagogastric junction
17 (22.1)
25 (32.9)
Fundus
14 (18.2)
16 (21.1)
Corpus
17 (22.1)
12 (15.8)
Antrum
29 (37.7)
22 (28.9)
The whole stomach
0 (0)
1 (1.3)
Borrmann type
0.233
Type 0
2 (2.6)
2 (2.6)
Type I
0 (0)
4 (5.3)
Type II
21 (27.3)
14 (18.4)
Type III
48 (63.2)
48 (63.2)
Type IV
6 (7.8)
8 (10.5)
ycT stage
0.722
T2
7 (9.1)
7 (9.2)
T3
23 (29.9)
17 (22.4)
T4a
42 (54.5)
45 (59.2)
T4b
5 (6.5)
7 (9.2)
ycN stage
0.955
N0
7 (9.1)
7 (9.2)
N1
35 (45.5)
32 (42.1)
N2
26 (33.8)
26 (34.2)
N3
9 (11.7)
11 (14.5)
ycTNM stage
0.939
IIA
7 (9.1)
7 (9.2)
IIB
7 (9.1)
7 (9.2)
III
58 (75.3)
55 (72.4)
IVA
5 (6.5)
7 (9.2)
BMI : body mass index; the yc stages were indicated by preoperative CT scan after neoadjuvant chemotherapy, and all staging was based on the eighth edition of the AJCC Cancer Staging Manual by the American Joint Committee on Cancer and International Union Against Cancer.